Key facts
- This page summarizes John Markels's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 Jun 2024, 16:24.
John Markels - 04 Jun 2024 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Reporting relationship
- Director
- Issuer ticker
- SGMO
- Reported as of
- 04 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Jun 2024, 16:24:55 UTC
- Prior SEC filing
- 03 Aug 2023
- Next SEC filing
- 18 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Markels filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 06 Jun 2024.
Change
- Previous filing in this sequence was filed on 03 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGMO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +25,000
- Change %
- +54%
- Price
- $0.000000
- Shares after
- 71,384
- Date
- 04 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SGMO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 04 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.5676
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
Footnote F2
The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.